New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...

The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Amgen (NASDAQ:AMGN), a prominent player in ... in adults with generalized myasthenia gravis (gMG), revealing sustained efficacy with twice-yearly dosing. The company, which has achieved impressive ...

(RTTNews) - Amgen Inc. (AMGN) Thursday announced positive data from the Phase 3 MINT study of Uplizna in adults with generalized myasthenia gravis (gMG). Myasthenia gravis is a chronic autoimmune ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...